Chromosome anomalies in mouse zygotes treated by growth hormone-releasing factor

Hum Reprod. 1992 Nov;7(10):1394-5. doi: 10.1093/oxfordjournals.humrep.a137580.

Abstract

The incidence of chromosome anomalies was studied in fertilized oocytes in two groups of hybrid mice in which superovulation was induced by gonadotrophins and growth hormone-releasing factor (GRF) supplementation or gonadotrophins alone (controls). The rate of fertilization was significantly higher among GRF-treated females than among controls (74.1 versus 84.7%; P < 0.013). Cytogenetic data were obtained in 262 fertilized oocytes (89 from control females and 173 from GRF-treated females). The frequency of aneuploidy, calculated as twice the frequency of hyperhaploidy was 2.31% in GRF-treated females and 2.24% in controls (NS). The use of GRF to treat female mice did not adversely affect the maturation process of oocytes nor did it induce an increased frequency of aneuploidy.

MeSH terms

  • Animals
  • Chromosome Aberrations*
  • Chromosomes / drug effects*
  • Female
  • Gonadotropins, Equine / therapeutic use
  • Growth Hormone-Releasing Hormone / pharmacology*
  • Growth Hormone-Releasing Hormone / therapeutic use
  • Maternal-Fetal Exchange
  • Mice
  • Ovulation Induction / methods
  • Pregnancy
  • Prenatal Exposure Delayed Effects*
  • Superovulation
  • Zygote / drug effects*

Substances

  • Gonadotropins, Equine
  • Growth Hormone-Releasing Hormone